Erleada - (60 mg; Tablets)

Generic Name	Apalutamide	Innovator	Janssen Pharma
Dosage	60 mg; Tablets	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** / ***	*** **, ****	******* / ********* ***	********* ********	******* **** **** *** *** ****
***** ******	*** / *********	*** **, ****	******* / ********* ***	****	*** ****** *** ****
******	*** / ***	*** **, ****	******* / ********* ***	********* ********	******* *** **** *** *** ****

Chronology Of Events